TA1 (Thymosin Alpha-1 (TA1 - Clinical Form))
The clinical designation for Thymosin Alpha-1, used internationally as an immune modulator. Approved for hepatitis B/C and used adjunctively in immunocompromised patients.
How it works
Activates TLR2/9 on dendritic cells, promotes T-cell differentiation, and enhances cytokine-mediated immune signaling cascades.
Key facts
- Molecular weight: 3108.3 Da
- Half-life: ~2-3 hours
- Bioavailability: ~85% subcutaneous
- Storage: Lyophilized: 2-8°C. Reconstituted: use immediately or refrigerate up to 24 hours.
Dosing overview
- Typical dose: 1.6 mg
- Frequency: 2x per week
- Duration: 6-12 months (chronic) or 4-8 weeks (general)
- Route: Subcutaneous injection
Protocol notes
- Standard is 1.6 mg twice weekly (the dose used in hepatitis trials).
- For general immune support, shorter 4-8 week runs at the same dose are common.
Reported benefits
- Standardized immune enhancement
- Proven antiviral adjunct
- Cancer immunotherapy support
- Vaccine response enhancement
Possible side effects
- Injection site discomfort
- Mild erythema
- Transient flu-like symptoms
Research
- TA1 as vaccine adjuvant in elderly (2020): Improved influenza vaccine antibody titers by 60% in immunosenescent elderly patients.
- Thymalfasin in hepatocellular carcinoma (2019): Improved overall survival when combined with standard chemotherapy in advanced HCC patients.
Compare TA1
Community discussions about TA1
- TA1 plus KLOW stack questions sleep dose splits injection sites - 6 comments
- Have others tried Thymosin Alpha‑1 to boost vaccine responses? - 4 comments
- TA1: A Real Immune Booster or Just Vaccine Adjuvant? - 7 comments
- TA1 injection site redness – what’s normal and when to worry - 7 comments
- Injection site reactions with subcutaneous peptides, how do you tell normal from concerning - 3 comments
- Ask the community about TA1
Research and educational reference only. Not medical advice.